TAK, US8740602052

Takeda sets October 29 results date for Takeda Pharmaceutical stock

Published on 10/27/2026 at 09:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Takeda presents fiscal 2026 second-quarter results on October 29. Fiscal 2026 guidance calls for JPY 4,640.0 billion revenue.

Pipeline update and reporting date

Takeda reported three Phase 3 psoriasis studies on October 23, 2026.
Fiscal 2026 guidance calls for JPY 4,640.0 billion of revenue and JPY 420.0 billion of operating profit.
Takeda Pharmaceutical stock trades at EUR 18.50 at 9:20 a.m. CET at Lang & Schwarz on October 27, 2026.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda Pharmaceutical (ISIN US8740602052) highlighted three Phase 3 psoriasis studies on October 23, 2026, while its next fiscal 2026 second-quarter results are scheduled for October 29. The pipeline update gives the stock a clinical-development angle before the company reports its latest operating figures.

Three studies shape the pipeline

According to Simply Wall St on October 23, Takeda released detailed clinical data across three key franchises. The material included Phase 4 VERDICT results for Entyvio, commercial availability of Orzeyful for narcolepsy in Japan and China, and Phase 2/3 IgGNITE findings for investigational TAK-881.

The same report identified the commercial tension behind the pipeline. Entyvio and Vyvanse face future pressure from biosimilars and generic competition, so newer products must scale while Takeda protects its established revenue base. The report described the balance between launch execution and portfolio pressure as a central issue for the company.

What does the results date add?

Takeda's fiscal 2026 guidance calls for JPY 4,640.0 billion of revenue, JPY 420.0 billion of operating profit, JPY 166.0 billion of net profit and JPY 104 of earnings per share, according to Simply Wall St. These are full-year guidance figures, not second-quarter results.

Takeda announced on October 15 that it will present fiscal 2026 second-quarter results on October 29. The release scheduled the presentation and question-and-answer session for 10:00 a.m. to 11:15 a.m. GMT, with materials due at 6:30 a.m. GMT.

Three dated company developments

On July 30, Takeda reported quarterly revenue of USD 7.50 billion and earnings per share of USD 0.95 against consensus of USD 0.41, according to MarketBeat. On October 15, the company set October 29 for its fiscal 2026 second-quarter presentation. On October 23, Takeda highlighted three Phase 3 psoriasis studies and related pipeline data.

Upcoming reporting dates

The next scheduled company event is the fiscal 2026 second-quarter results presentation on October 29, 2026. Takeda's investor page also identifies that date for the earnings announcement and webcast.

Stock quote and investor context

Takeda Pharmaceutical stock was trading at EUR 18.50 at Lang & Schwarz on October 27, 2026 at 9:20 a.m. CET. The price represents the valid intraday euro indication for investors in Germany; the Xetra reference close and a corresponding daily percentage are omitted from this report.

The further course of trading is shown by the continuously updated real-time quote of Takeda Pharmaceutical stock.